We are live on ! Find out more

Foghorn Therapeutics

FHTX

Market cap $116M

1.95 USD

-0.05

2.5%

At close Updated Oct 12, 10:03 AM EDT

1 day

-2.5%

5 days

-2.5%

1 month

-55.28%

3 months

-64.15%

6 months

-58.42%

Year to date

-62.43%

1 year

-54.55%

5 years

-84.21%

10 years

-89.24%

About: Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Employees: 106

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 50%

Negative 25%

FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $FHTX--FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law.

FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data.

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug

Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show ‌enough benefit in an early-stage trial.

Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase.

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Zacks Investment Research

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Zacks Investment Research

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Zacks Investment Research

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

See News Rankings

Price charts implemented using Lightweight Charts™